{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:30:51Z","timestamp":1757543451950,"version":"3.41.2"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2023,6,20]]},"abstract":"<jats:p>We present the first performance evaluation results for omadacycline on the VITEK 2 and VITEK 2 Compact Systems (bioM\u00e9rieux, Inc.). The trial was conducted at four external sites and one internal site.<\/jats:p>","DOI":"10.1128\/jcm.00174-23","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:15:28Z","timestamp":1683728128000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Multicenter Clinical Performance Evaluation of Omadacycline Susceptibility Testing of\n            <i>Enterobacterales<\/i>\n            on VITEK 2 Systems"],"prefix":"10.1128","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8910-9648","authenticated-orcid":true,"given":"Edith","family":"Csiki-Fejer","sequence":"first","affiliation":[{"name":"bioM\u00e9rieux, Inc., Hazelwood, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Traczewski","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Institute, Inc., Wilsonville, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-2968","authenticated-orcid":true,"given":"Gary W.","family":"Procop","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Davis","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2701","authenticated-orcid":true,"given":"Meredith","family":"Hackel","sequence":"additional","affiliation":[{"name":"IHMA Inc., Schaumburg, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5373-3361","authenticated-orcid":true,"given":"Hari P.","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, Inc., Hazelwood, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Pincus","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, Inc., Hazelwood, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Paratek Pharmaceuticals I. 2021. NUZYRA (omadacycline) prescribing information."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1900188"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2085881"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020063"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202000014"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.808744"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01119-9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01257-4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02749-1"},{"key":"e_1_3_3_16_2","first-page":"15","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, p. 15\u201364, CLSI standard M07 11th ed. Clinical and Laboratory Standards Institute. Wayne, PA.","edition":"11"},{"key":"e_1_3_3_17_2","first-page":"9","volume-title":"Guidance for industry and FDA. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems","author":"FDA","year":"2009","unstructured":"FDA. 2009. Guidance for industry and FDA. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems, p. 9\u201342. Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_18_2","unstructured":"ISO. 2007. ISO 20776\u20132:2007. Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 2: evaluation of performance of antimicrobial susceptibility test devices. https:\/\/www.iso.org\/obp\/ui\/#iso:std:iso:20776:-2:ed-2:v1:en."},{"key":"e_1_3_3_19_2","first-page":"685","article-title":"Semiautomatic microtechnique for serial dilution-antibiotic sensitivity testing in the clinical laboratory","volume":"72","author":"MacLowry JD","year":"1968","unstructured":"MacLowry JD, Marsh HH. 1968. Semiautomatic microtechnique for serial dilution-antibiotic sensitivity testing in the clinical laboratory. J Lab Clin Med 72:685\u2013687.","journal-title":"J Lab Clin Med"},{"key":"e_1_3_3_20_2","unstructured":"Barry AL Hoeprich PD Saubolle MA. 1976. The antimicrobic susceptibility test: principles and practices."},{"key":"e_1_3_3_21_2","first-page":"190","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing, CLSI Supplement M100","author":"CLSI","year":"2021","unstructured":"CLSI. 2021. Performance Standards for Antimicrobial Susceptibility Testing, CLSI Supplement M100, p. 190\u2013192. 31st ed.","edition":"31"},{"key":"e_1_3_3_22_2","volume-title":"Antibacterial susceptibility test interpretive criteria Omadacycline Injection and Oral Products | FDA","author":"FDA","year":"2022","unstructured":"FDA. 2022. U.S. Food and Drug Administration identified breakpoints for omadacycline. Antibacterial susceptibility test interpretive criteria Omadacycline Injection and Oral Products | FDA. https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products. Accessed 9 January 2023."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0068-2022"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00174-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00174-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T13:00:57Z","timestamp":1687266057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00174-23"}},"subtitle":[],"editor":[{"given":"Erin","family":"McElvania","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,20]]}},"alternative-id":["10.1128\/jcm.00174-23"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00174-23","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"type":"print","value":"0095-1137"},{"type":"electronic","value":"1098-660X"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"2023-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00174-23"}}